SOBI:STO
Biovitrum
428,40Â SEK
arrow_upward
+1,42%(+6,00) 1Â D
9. okt., 17:29:43 GMT+2 · SEK
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for SOBI …
Ã…pne
427,60Â SEK
Høy
431,60Â SEK
Lav
426,60Â SEK
Markedsverdi
153,21Â mrd.
Snittvolum
268,70k
Volum
179,02k
P/E-forhold
114,42
52 u høy
487,00Â SEK
52Â u lav
293,60Â SEK
EPS
3,74Â SEK
Utestående aksjer
357,64Â mill.
Antall ansatte
2k
Ã…pne
427,60Â SEK
Høy
431,60Â SEK
Lav
426,60Â SEK
Markedsverdi
153,21Â mrd.
Snittvolum
268,70k
Volum
179,02k
P/E-forhold
114,42
52 u høy
487,00Â SEK
52Â u lav
293,60Â SEK
EPS
3,74Â SEK
Utestående aksjer
357,64Â mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 2 døgn siden
Dow stiger 423 poeng etter teknologireprise, telekomaksjer faller på SpaceX
Invezz
·
for 3 døgn siden
AI-boblen kan sprekke i 2027 og sende S&P 500 ned til 5 000, advarer strateg
Invezz
·
for 3 døgn siden
Dow åpner 120 poeng lavere etter oljeoppgang og høyere Treasury-avkastning
Seeking Alpha
·
for 1 time siden
S&P 500: The Quick And Easy Days Are Over (SP500)
Profil
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
Om Biovitrum